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Abstract
Background: Surotomycin, a novel, orally administered, cyclic, lipopeptide antibacterial in development for the
treatment of Clostridium difficile-associated diarrhea, has demonstrated minimal intestinal absorption in animal models.
Methods: Safety, tolerability, and plasma pharmacokinetics of single and multiple ascending oral doses (SAD/MAD) of
surotomycin in healthy volunteers were characterized in two randomized, double-blind, placebo-controlled, phase 1
studies.
Results: Participants were sequentially enrolled into one of four SAD (500, 1000, 2000, 4000 mg surotomycin) or three
MAD (250, 500, 1000 mg surotomycin twice/day for 14 days) cohorts. Ten subjects were randomized 4:1 into each
cohort to receive surotomycin or placebo. Surotomycin plasma concentrations rose as dose increased (maximum
plasma concentration [Cmax]: 10.5, 21.5, 66.6, and 86.7 ng/mL). Systemic levels were generally low, with peak
median surotomycin plasma concentrations observed 6–12 h after the first dose. In the MAD study, surotomycin plasma
concentrations were higher on day 14 (Cmax: 25.5, 37.6, and 93.5 ng/mL) than on day 1 (Cmax: 6.8, 11.0, and 21.1 ng/mL
for increasing doses), indicating accumulation. In the SAD study, <0.01% of the administered dose was recovered in
urine. Mean surotomycin stool concentration from the 1000 mg MAD cohort was 6394 μg/g on day 5. Both cohorts
were well tolerated with all adverse events reported as mild to moderate.
Conclusion: Both SAD and MAD studies of surotomycin demonstrated minimal systemic exposure, with feces
the primary route of elimination following oral administration; consistent with observations with similar compounds,
such as fidaxomicin. Results of these phase 1 studies support the continued clinical development of surotomycin for
the treatment of Clostridium difficile-associated diarrhea.
Trial registration: NCT02835118 and NCT02835105. Retrospectively registered, July 13 2016.
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Background
Clostridium difficile-associated diarrhea (CDAD) is a key
cause of hospital- and community-acquired diarrhea and
is associated with longer length of hospital stay, increased
medical costs, and high rates of morbidity and mortality
[1–3]. Attributable healthcare costs of CDAD in the
United States are estimated to be between $433 million
and $797 million per year [4]. Over the past decade, the
incidence and severity of CDAD has increased across the
United States, Canada, and Europe [5–7].
Despite having a clinical response rate of ~73 to 85%,
vancomycin and metronidazole treatments are associated
with recurrent CDAD in up to 45% of patients [8–11]. Ag-
gressive vancomycin and metronidazole treatment is also
associated with disruption of the intestinal microbiota and
can promote colonization by vancomycin-resistant entero-
cocci, highlighting the need for novel treatment options
[12, 13]. An ideal agent for the treatment of CDAD should
be associated with low levels of systemic absorption,
resulting in high concentrations of the drug in the colon,
combined with a narrow spectrum of activity against C.
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difficile to limit its impact on the established intestinal
microbiota.
Surotomycin (CB-183,315; MK-4261) is a novel, orally
administered, cyclic, lipopeptide antibacterial currently
in phase 3 development for the treatment of patients
with CDAD [14]. Surotomycin has a fourfold greater in
vitro potency than vancomycin against C. difficile (mini-
mum inhibitory concentration at which 90% of the isolates
were inhibited [MIC90] = 0.5 μg/mL vs 2.0 μg/mL) and
other Gram-positive bacteria with minimal impact on the
Gram-negative organisms of the intestinal microbiota [15,
16]. Surotomycin, given orally, has been shown to be
highly effective against both initial and relapsing hamster
CDAD, with potency similar to vancomycin [14]. Suroto-
mycin has previously demonstrated minimal intestinal ab-
sorption (<1%) in rats and dogs (Yin N et al., ICAAC
2010, unpublished data). The objectives of these phase 1
studies were to characterize the safety, tolerability, and
plasma pharmacokinetic (PK) profile of single and multiple
ascending oral doses of surotomycin in healthy volunteers.
Methods
Study design and participants
Written informed consent was obtained from all partici-
pants, and the protocols were approved by the institutional
review board of the study site (West Coast Clinical Tri-
als, LLC, Cypress, CA, USA). These randomized,
double-blind, placebo-controlled, phase 1 studies con-
sisted of a single ascending dose (SAD) study (protocol
number LCD-SAD-08-04, NCT02835105) and a mul-
tiple ascending dose (MAD) study (protocol number
LCD-MAD-08-08, NCT02835118). Both studies were
conducted in accordance with the ethical principles ori-
ginating from the Declaration of Helsinki and its
amendments, consistent with Good Clinical Practices
and local regulatory requirements.
Male and female subjects aged 18–75 years were eligible
for these studies if considered by the investigator to be in
good health with unremarkable current and past medical
history before the first day of study. Subjects were required
to have no clinically significant abnormalities in prestudy
physical examination, electrocardiogram (ECG), and
laboratory evaluations. Subjects with findings outside of
the normal range were included in the study only if these
findings were deemed not clinically significant by the in-
vestigator or medical monitor. Subjects had no evidence of
prior chronic gastrointestinal inflammatory disease.
Exclusion criteria included incidence of C. difficile dis-
ease within 1 year before study entry (SAD); prior expos-
ure to surotomycin (MAD); known hypersensitivity to
lipopeptide antibacterials; any comorbid disease judged by
the investigator to be clinically significant; any concomi-
tant medication, except low-dose aspirin, paracetamol, and
multivitamins, in the 2 weeks before dosing (investigator-
and medical monitor-approved concomitant medications
were permitted in patients aged 49 years and above); or
any antibiotic within 30 days before the first dose of the
study drug. Women who were unwilling or unable to use
an acceptable method to avoid pregnancy or who were
pregnant or lactating during the conduct of the study and
until 1 month after last surotomycin dose were excluded.
For the SAD study, eligible subjects were sequentially
enrolled into 1 of 4 dose cohorts: 500 mg, 1000 mg,
2000 mg, or 4000 mg surotomycin (Fig. 1a). In total, 10
subjects were intended to be randomized into each dose
cohort in a 4:1 ratio to receive surotomycin (n = 8) or
placebo (n = 2). At least 24 h before dosing the first
full cohort, 2 subjects received surotomycin or pla-
cebo (randomized 1:1). The remaining 8 subjects were
randomly assigned to surotomycin (n = 7) or placebo
(n = 1) only if no significant safety findings or clinic-
ally significant abnormal laboratory values were reported
for the first 2 subjects. Randomization was assigned by
blinded study personnel and stratified by gender to
achieve an equal number of male and female subjects in
each cohort. Subjects aged 18–49 years and 50–75 years
were equally distributed in each dosing cohort. Subjects
received a single dose of surotomycin or placebo during
the morning of day 1 (1 h after breakfast) and were
followed as an inpatient through day 4 when they were
discharged to return for a follow-up visit on day 8.
Eligible subjects were recruited and sequentially en-
rolled into 1 of 3 MAD dose cohorts: 250 mg, 500 mg,
or 1000 mg surotomycin twice daily (BID) (Fig. 1b). A
total of 10 subjects were randomized (4:1) to receive sur-
otomycin (n = 8) or placebo (n = 2) in each cohort.
Randomization was also stratified by gender and distrib-
uted by age to ensure that dosing cohorts were balanced.
Subjects were dosed BID, once in the morning and once
in the evening, for 14 consecutive days, with at least 8
ounces of water and approximately 1 h after breakfast
and 1 h after dinner. Subjects were observed as inpa-
tients through day 15 and were then discharged to re-
turn for follow-up on day 21.
In both studies, dose escalation to the next cohort oc-
curred sequentially, and only after review of key safety
data obtained from the previous cohort indicated that it
was safe to proceed. The investigator and all personnel
involved in the clinical or analytical evaluations of the
study remained blinded to treatment until all cohorts
had completed and the database was locked. Treatment
doses were administered according to a randomization
code by a pharmacist who was not an investigator or in-
volved in study evaluations.
Pharmacokinetic analysis
Any subject receiving at least one full dose of the study
drug was included in the PK analysis population. PK
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analysis during the SAD study was conducted on serial
plasma samples collected predose and at 30 min, 1, 2, 4,
6, 8, 12, 24, 48, and 72 h after dosing, and analyzed using
a validated liquid chromatography-tandem mass spec-
trometry (LC/MS/MS) method, with a lower limit of
quantification (LLOQ) of 1 ng/mL. Urine and stool sam-
ples were also collected during this period and analyzed
using LC/MS/MS. Urine and feces were collected for
7 days after dose administration. The samples were ana-
lyzed using an API 5000 triple quadrupole mass spectrom-
eter (Applied Biosystems/ScieEx, Concord, ON, Canada)
using electrospray ionization in positive ion mode. Ana-
lystTM software (version 1.4.2., Applied Biosystems, Foster
City, CA, USA) was used for data acquisition. In total, 8
calibration solutions with a range of 1.00 ng/mL to
1000 ng/mL were used as internal standards in addition to
a blank. Inter-assay bias was determined to be –2.6 to
2.5% with inter-assay precision of 3.9 to 9.4%.
During the MAD study, serial plasma samples for PK
analysis were collected predose and at 30 min, 3, 6, and 9 h
after the morning dose on days 1 and 14, and before the
morning dose on days 4, 7, 10, and 12 (trough levels). Stool
was also collected in its entirety from all bowel movements
for PK analysis following the morning dose on day 5
through predose day 6 in the 1000-mg BID dose cohort.
Samples were analyzed using the same bioanalytical LC/
MS/MS method as in the SAD study (LLOQ of 1 ng/mL).
Plasma PK parameters were calculated using standard
noncompartmental methods in a validated version of
WinNonlin (version 5.2, Pharsight, Mountain View, CA,
USA). All concentrations that were below the LLOQ
prior to the first detectable concentration were assigned
a value of 0. All concentrations that were below the
LLOQ after the first quantifiable concentration were
designated as missing and replaced with a period. Ac-
tual sample collection times were used in the analysis
of the concentration versus time profiles for individ-
ual subjects. Integration of plasma concentrations ver-
sus time was conducted using the linear-up, log-down
function in WinNonlin. The following parameters were
determined: maximum plasma concentration (Cmax), time
of Cmax (Tmax), area under the concentration-time curve
(AUC) from 0 to last measurable plasma concentration
(AUC0-t), AUC from 0 to infinity (AUC0-∞), percent of
dose excreted in the urine, and terminal exponential
half-life (t½).
Fig. 1 Single ascending dose (a) and multiple ascending dose (b) study overviews
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Sample sizes were chosen based primarily on clinical con-
siderations and were considered sufficient for the explora-
tory evaluation of single- and multiple-dose safety and PK.
Safety analysis
Safety was monitored throughout the studies and on re-
turn for follow-up assessment on day 8 (SAD group) or
day 21 (MAD group), by observation or reports of adverse
events (AEs), and by changes in physical examination
findings, vital signs, ECG, and laboratory tests. Concomi-
tant medications and procedures were recorded. Any sub-
ject who received any dose of the study drug was included
in the safety analysis population.
Statistics
Statistical methods were primarily descriptive and no for-
mal hypothesis tests were planned or completed. Data were
summarized and analyzed using Statistical Analysis System
SAS® (version 9.1.3; SAS Institute, Cary, NC, USA).
Results
Subject demographics and characteristics
Both study groups were enrolled to completion with four
10-subject cohorts randomized in the SAD study and
three cohorts of the same size randomized in the MAD
study. All 40 subjects in the SAD group received all
scheduled study medication. One subject (2000 mg)
withdrew from the study early and missed the follow-up
visit due to a family emergency. In all, 28 of 30 subjects
completed the MAD study as planned. One subject
(500 mg BID) discontinued treatment due to AEs of
anxiety and dyspnea after 5 doses, and one subject
(250 mg BID) did not complete the day-21 follow-up
visit (considered lost to follow-up).
Subject demographics and baseline characteristics are
summarized in Table 1. Half of all subjects enrolled in
both studies were male, and treatment cohorts were gen-
erally well balanced with respect to age, race, and body
mass index (BMI). In the SAD study, across all subjects
who received surotomycin, the mean age was 42.9 years
(range: 19 to 69 years) and mean BMI was 25.5 kg/m2.
By comparison, subjects receiving placebo in the SAD
study had a mean age of 28.3 years (range: 18 to 58 years)
and a mean BMI of 23.9 kg/m2. For all subjects who re-
ceived surotomycin in the MAD study, the mean age
was 47.6 years (range: 20 to 70 years) and mean BMI
was 27.4 kg/m2. Participants in the MAD study receiving
placebo had a mean age of 48.8 years (range: 25 to
70 years) and a BMI of 25.8 kg/m2.
Pharmacokinetic results
The median plasma concentration-time profiles of suro-
tomycin following administration of single oral doses
(SAD) and following administration of a single dose and
repeated doses (MAD) are presented in Fig. 2. However,
although quantifiable levels of surotomycin were ob-
served in 4 subjects in the SAD 2 g cohort and 6 sub-
jects in the 4 g cohort, a full plasma concentration-time
Table 1 Demographics and baseline characteristics














































Median 47.50 37.00 41.50 35.50 43.00 25.00 47.00 53.00 50.50 50.50 50.50
Min, max 23.0, 66.0 19.0, 67.0 21.0, 62.0 21.0, 69.0 19.0, 69.0 18.0, 58.0 27.0, 53.0 20.0, 69.0 29.0, 70.0 20.0, 70.0 25.0, 70.0
Sex, n (%)
Male 4 (50.0) 4 (50.0) 4 (50.0) 4 (50.0) 16 (50.0) 4 (50.0) 4 (50.0) 4 (50.0) 4 (50.0) 12 (50.0) 3 (50.0)
Race, n (%)
Asian 0 0 1 (12.5) 2 (25.0) 3 (9.4) 0 1 (12.5) 0 0 1 (4.2) 2 (33.3)
Black 2 (25.0) 2 (25.0) 1 (12.5) 0 5 (15.6) 2 (25.0) 1 (12.5) 2 (25.0) 2 (25.0) 5 (20.8) 1 (16.7)
White 6 (75.0) 5 (62.5) 6 (75.0) 6 (75.0) 23 (71.9) 6 (75.0) 6 (75.0) 6 (75.0) 6 (75.0) 18 (75.0) 3 (50.0)
Other 0 1 (12.5) 0 0 1 (3.1) 0 0 0 0 0 0
BMI (kg/m2)






















Median 24.29 25.31 22.37 27.51 25.50 22.17 27.70 27.80 25.90 27.40 25.55
Min, max 22.7, 32.4 17.9, 28.3 19.8, 27.6 22.0, 25.3 17.9, 35.3 20.2, 32.2 25.5, 29.7 21.6, 35.2 23.6, 32.7 21.6, 35.2 19.8, 31.7
BID Twice daily, BMI Body mass index, SD Standard deviation
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curve was obtained in only 2 subjects, 1 in each dose co-
hort. Following a brief lag after the administration of a sin-
gle dose, median plasma concentrations of surotomycin
were quantifiable and seemed to increase with an increase
in dose (Fig. 2a and b). Peak median plasma surotomycin
concentrations were observed from 6 to 12 h after the first
single dose in both the SAD and MAD groups. For pa-
tients receiving repeated surotomycin dosing, the median
plasma concentration versus time profile on day 14 was
flat (Fig. 2c), indicating that steady state had been reached
and that the concentrations were essentially steady or con-
stant during the dosing interval.
The PK parameters of surotomycin following administra-
tion of single oral doses (SAD) and a single oral dose and
repeated oral doses (MAD) are summarized in Table 2.
In the SAD group, median Cmax ranged from 10.5 ng/
mL in the 500-mg dose cohort to 86.7 ng/mL in the
4000-mg dose cohort, and the AUC0-∞ ranged from
317 ng*h/mL in the 500-mg dose cohort to 2572 ng*h/
mL in the 4000-mg dose cohort. While the overall ex-
posure of surotomycin as measured by Cmax and
AUC0–∞ increased with increases in dose, the median
elimination half-life was independent of the dose admin-
istered and ranged between 14.8 and 21.1 h. In the
MAD study, Cmax on day 1 (following a single dose) was
consistent with the findings of the SAD group and
ranged from 6.8 ng/mL to 21.0 ng/mL. On day 14, the
median Cmax ranged from 25.5 ng/mL to 93.5 ng/mL,
possibly suggesting an accumulation of surotomycin in
the body following repeated dosing. No additional PK
parameters for surotomycin could be computed due to
the nature of the plasma concentration-time profile on
days 1 and 14, and limited sampling. Figure 3 shows the
dose-normalized Cmax and AUC0–∞ for surotomycin
after a single dose (SAD), indicating that surotomycin
exposure increased in a dose-dependent manner.
In the SAD study, concentrations of surotomycin in
the urine were detected in 12 of 32 subjects treated, and
the median cumulative amount of the administered dose
recovered in the urine was <0.01% over a 7-day period.
The median cumulative fraction of the administered sur-
otomycin dose excreted in the feces over a 4-day period
ranged from 20.8 to 60.2% after a single dose (SAD).
Stool levels of surotomycin increased proportionally with
the dose administered. In the MAD study, the mean
concentration of surotomycin from the 1000-mg BID
dose cohort on day 5 was 6394 μg/g.
Safety analysis
During the SAD study, a total of 13 (32.5%) subjects ex-
perienced at least one AE. Ten subjects had AEs that
were assessed as treatment-related, including 9 (28.1%)
of the 32 subjects who received surotomycin and 1
(12.5%) of the 8 subjects who received placebo. The
most commonly reported treatment-related AE was diar-
rhea, reported in 5 (15.6%) surotomycin subjects and
none of the placebo subjects (Table 3). Increased trans-
aminases were reported in 2 (6.3%) of the 32 subjects
who received surotomycin.
Although a total of 18 (60.0%) subjects experienced at
least one AE during the MAD study, all reported AEs
were considered unrelated to the study drug. The most
Fig. 2 Median plasma concentration versus time profiles for
surotomycin following administration of (a) a single dose, (b) the first
dose on day 1, and (c) the morning dose on day 14
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common AE in the MAD group was headache, reported
in 2 (8.3%) of the 24 subjects who received surotomycin
(1 each in the 250-mg BID and 500-mg BID dose co-
horts) and 2 (33.3%) of the 6 placebo subjects (Table 3).
Constipation, back pain, oropharyngeal pain, and prur-
itus were each reported in 2 (8.3%) of the subjects who
received surotomycin.
All reported AEs in both studies were mild to moder-
ate in severity. No serious AEs were reported and none
of the subjects discontinued the study due to AEs in the
SAD group. One subject in the MAD group (500 mg
BID) discontinued due to transient moderate anxiety
and associated mild dyspnea. The events were reported
2 h after the 5th dose of study treatment. The anxiety re-
solved within 4 h and the dyspnea within 3 min, both
without the need for additional treatment.
Discussion
In both SAD and MAD studies, Cmax and AUC values
were low, demonstrating the limited systemic exposure
and that less than 0.01% of the administered compound
was excreted in the urine. In addition to the clinical
findings, complementary information obtained from pre-
clinical animal studies with radiolabeled surotomycin
suggests poor systemic absorption and exposure without
elimination through the hepatobiliary route (Merck &
Co., Inc., Kenilworth, NJ, USA, unpublished data). These
results support the insignificant absorption of suroto-
mycin observed in these clinical trials. Peak median
surotomycin plasma concentrations were achieved be-
tween 6 and 12 h post-dose, also suggesting that a
small amount is absorbed in the lower gastrointestinal
tract in healthy volunteers.
In the SAD study, there appeared to be a degree of
dose-non-linearity in surotomycin plasma concentrations,
appearing to peak at the 2000-mg dose and decrease with
Table 2 Summary of pharmacokinetic parameters for surotomycin. Following administration of a single dose and following
administration of a single dose (day 1) and multiple doses (day 14)
Single ascending dose Multiple ascending dose
Day 1 Day 14































































































ND ND ND ND ND ND
AUC Area under the concentration-time curve, AUC0-t, AUC from 0 to last measurable plasma concentration; AUC0-∞, AUC from 0 to infinity; BID Twice daily, Cmax
Maximum plasma concentration, ND Not determined, Tmax Time to maximum plasma concentration
Fig. 3 Dose-normalized (a) Cmax and (b) AUC0–∞ of surotomycin
following administration of single oral doses of surotomycin.
AUC0–∞, area under the concentration-time curve from 0 to
infinity Cmax, maximum plasma concentration
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the 4000-mg dose (Fig. 3). However, these data should be
interpreted with care due to the very low concentrations
detected in this study. In the SAD study at the 2000-mg
and 4000-mg doses, a full plasma concentration-time
curve could be determined from only two subjects. In
addition, the concentrations detected were less than 3-
fold of the LLOQ and thus no inferences could be made
from these data.
As expected with a molecule with minimal absorp-
tion, stool levels of surotomycin increased proportion-
ally with the dose administered. During the SAD and
MAD studies, substantial concentrations of surotomy-
cin were observed in the stool, indicating that this is
the major route of elimination for orally dosed suroto-
mycin. Assuming dose proportionality, stool concentra-
tions of surotomycin should greatly exceed the MIC90
for C. difficile, suggesting that 250-mg BID oral dosing
of surotomycin will be effective for the treatment of
CDAD. Indeed, the low systemic exposure observed
here did not come as much of a surprise, as it has been
shown previously that in rats bioavailability after oral
administration is very low (Yin N et al., ICAAC 2010,
unpublished data).
Single oral doses of surotomycin (500 mg, 1000 mg,
2000 mg, or 4000 mg) were well tolerated, with all AEs
reported as mild to moderate in severity. The most
commonly reported AE in the SAD group was diarrhea,
but this was not dose-dependent. Differences in AEs
reported between the surotomycin cohorts and the pla-
cebo cohort may have been due to differences in the
ages of subjects in the two groups (mean age ± standard
deviation: surotomycin, 42.9 ± 16.89 and placebo, 28.3
± 13.25), consistent with the observation that older
populations have increased susceptibility to gastrointes-
tinal complications of comorbid disease [17]. Multiple
oral doses of surotomycin (250 mg, 500 mg, 1000 mg
BID) were also well tolerated in healthy adult volun-
teers, with all AEs reported as mild to moderate in se-
verity and no AEs reported as being related to the
study drug.
Table 3 Treatment-emergent AEs by system organ class and preferred term (safety population). Observed in ≥2 subjects in the a)
SAD and b) MAD study
System organ class Preferred term Single ascending dose
500 mg (n = 8)
n (%)
1000 mg (n = 8)
n (%)
2000 mg (n = 8)
n (%)
4000 mg (n = 8)
n (%)
Placebo (n = 8)
n (%)
At least one TEAE 3 (37.5) 0 5 (62.5) 3 (37.5) 2 (25.0)
Gastrointestinal disorders 2 (25.0) 0 3 (37.5) 1 (12.5) 1 (12.5)
Diarrhea 1 (12.5) 0 3 (37.5) 1 (12.5) 0
Infections and infestations 0 0 0 2 (25.0) 0
Investigations 0 0 1 (12.5) 1 (12.5) 0
Transaminase increased 0 0 1 (12.5) 1 (12.5) 0
System organ class Preferred term Multiple ascending
dose
250 mg BID (n = 8)
n (%)
500 mg BID (n = 8)
n (%)
1000 mg BID (n = 8)
n (%)
Placebo (n = 6)
n (%)
At least one TEAE 4 (50.0) 6 (75.0) 5 (62.5) 3 (50.0)
Nervous system disorders 2 (25.0) 1 (12.5) 2 (25.0) 2 (33.3)
Headache 1 (12.5) 1 (12.5) 0 2 (33.3)
Gastrointestinal disorders 2 (25.0) 0 2 (25.0) 3 (50.0)
Respiratory, thoracic, and mediastinal
disorders
0 2 (25.0) 2 (25.0) 0
Oropharyngeal pain 0 1 (12.5) 1 (12.5) 0
General disorders and administration- site
conditions
0 0 2 (25.0) 1 (16.7)
Infections and infestations 0 1 (12.5) 1 (12.5) 0
Musculoskeletal and connective tissue
disorders
2 (25.0) 2 (25.0) 0 0
Back pain 1 (12.5) 1 (12.5) 0 0
Skin and subcutaneous tissue disorders 0 1 (12.5) 1 (12.5) 0
Pruritus 0 1 (12.5) 1 (12.5) 0
BID Twice daily, MAD multiple ascending oral dose; SAD single ascending dose; TEAE Treatment-emergent adverse advent
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Conclusion
In summary, single (500 mg, 1000 mg, 2000 mg, 4000 mg)
and multiple doses (250 mg, 500 mg, 1000 mg BID) of the
novel lipopeptide antibiotic surotomycin demonstrated
minimal systemic exposure, with the feces being the pri-
mary route of elimination following oral administration.
These results are consistent with those observed with
similar compounds, such as fidaxomicin. Results of these
phase 1 studies support the continued clinical develop-
ment of surotomycin for the treatment of CDAD. In
addition to defining the efficacy profile of surotomycin
against CDAD, currently being addressed in phase 3 trials,
additional studies will determine the in vivo effects of sur-
otomycin on intestinal microbiota.
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